AVM&

Advertiser / Brand · vs · Private Equity, VC & Investor

Aviva vs M&G

Structured technology and market comparison · 2026

Direct Feature Comparison

Aviva · vs · M&G
Market Cluster / Sector
AvivaAdvertiser / Brand
M&GPrivate Equity, VC & Investor
Platform Focus
Aviva

UK insurance, savings and retirement services group.

M&G

UK savings, insurance and asset management group.

Company Size
Aviva>5,000 employees
M&G>5,000 employees
Headquarters
AvivaUnited Kingdom
M&GUnited Kingdom
Year Founded
Aviva1696
M&G2017

Analyze all overlapping signals and tech stacks for Aviva and M&G

Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.

Compare in PlatformInstant access · 1-click via Google/LinkedIn

Comparison Analysis

What is the main difference between Aviva and M&G?

When comparing Aviva and M&G, both platforms operate within the Advertiser / Brand and Private Equity, VC & Investor ecosystem. Aviva is positioned as UK insurance, savings and retirement services group, whereas M&G focuses on UK savings, insurance and asset management group. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.

What are the top alternatives to Aviva and M&G?

When evaluating Aviva and M&G, enterprise buyers also consider other platforms in Advertiser / Brand and Private Equity, VC & Investor. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.

How do the corporate scale, structure, and headquarters of Aviva and M&G compare?

Aviva is headquartered in United Kingdom (founded in 1696) with >5,000 employees. M&G is based in United Kingdom (founded in 2017) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.

Market Signals

Recent Market Signals & Activity: Aviva vs M&G

Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.

AV

Aviva

Recent Signals

M&

M&G

Recent Signals

  • ·Tech.eu (European Tech & Deals)Financials

    bit.bio Raises $25M Series D for Cell Models

    bit.bio, a human cell programming company, announced it has closed a $25 million Series D funding round. The investment will be used to expand its portfolio of human cell models and increase access to its technology for pharmaceutical, biotechnology, and research organizations. The round includes participation from existing investor M&G Investments and Dr Jonathan Milner, founder and former CEO of Abcam. The company's opti-ox™ platform enables the production of defined human cell types at scale, and its ioCells portfolio includes over 50 cell types for drug discovery and disease research. The funding comes as AI accelerates drug candidate identification and there is growing demand for alternatives to animal testing.

    • bit.bio closed a $25 million Series D funding round.
    • The round includes participation from M&G Investments and Dr Jonathan Milner.
    • bit.bio's opti-ox™ platform enables scalable production of defined human cell types.

Compare their exact ecosystem overlaps.

Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Aviva and M&G share across the market ecosystem.